Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PACCELIO - FDG-PET based small volume accelerated immuno-chemoradiotherapy in locally advanced NSCLC
2022-003408-33Phase 2Active
- Sponsor
- TheraOp gGmbH
- Start
- Dec 2022
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of durvalumab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by TheraOp gGmbH. Primary endpoint: Completion rate. Started Dec 2022; status: active.
02
Drugs
durvalumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2022-003408-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-003408-33.